Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DOUBLE-BLIND DOSE-FINDING STUDY OF OLSALAZINE VERSUS SULFASALAZINE ASMAINTENANCE THERAPY FOR ULCERATIVE-COLITIS
Autore:
KRUIS W; JUDMAIER G; KAYASSEH L; STOLTE M; THEUER D; SCHEURLEN C; HENTSCHEL E; KRATOCHVIL P;
Indirizzi:
EVANGEL KRANKENHAUS KALK,BUCHFORSTSTR 2 W-5000 COLOGNE 91 GERMANY
Titolo Testata:
European journal of gastroenterology & hepatology
fascicolo: 5, volume: 7, anno: 1995,
pagine: 391 - 396
SICI:
0954-691X(1995)7:5<391:DDSOOV>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Keywords:
INACTIVE ULCERATIVE COLITIS; RELAPSE PREVENTION; OLSALAZINE; DOSE-FINDING; SULFASALAZINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
W. Kruis et al., "DOUBLE-BLIND DOSE-FINDING STUDY OF OLSALAZINE VERSUS SULFASALAZINE ASMAINTENANCE THERAPY FOR ULCERATIVE-COLITIS", European journal of gastroenterology & hepatology, 7(5), 1995, pp. 391-396

Abstract

Objective: To determine the therapeutic efficacy and safety of three doses of olsalazine compared with the standard dose of sulphasalazine. Design: Randomized double-blind multicentre 6-month study comparing three doses of olsalazine (0.5, 1.25 and 2.0 g daily) and sulphasalazine 2.0 g daily for maintaining remission in patients with ulcerative colitis. Setting: Public hospitals and private practices in Germany, Austria and Switzerland. Patients: A total of 162 patients with ulcerative colitis in remission. Results: According to intention-to-treat analysis, the failure rates of the different treatment groups were not significantly different (36, 49 and 24% for 0.5, 1.25 and 2.0 g olsalazinedaily and 32% for 2.0 g sulphasalazine daily). Olsalazine and sulphasalazine showed a tendency towards lower failure rates in extended (28%) than in distal disease (44%). The withdrawal rate due to adverse effects was 4%, the most frequent single event being diarrhoea (2.5, 5.2 and 11.7% for 0.5, 1.25 and 2.0 g olsalazine daily and 0% for sulphasalazine daily). Conclusion: This study found no significant differencesbetween the therapeutic efficacy or safety of 0.5-2.0 g olsalazine daily. Because of its sulpha-free formulation olsalazine may, however, be preferred to sulphasalazine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 06:19:17